PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells

Changjiang Qin1, Zhiyu Ji1✉, Ertao Zhai2, Kaiwu Xu2, Yijie Zhang3, Quanying Li1, Hong Jing4, Xiaoliang Wang5 and Xinming Song2

© The Author(s) 2022

The use of PARP inhibitors in combination with radiotherapy is a promising strategy to locally enhance DNA damage in tumors. Loss of XRCC2 compromises DNA damage repairs, and induced DNA damage burdens may increase the reliance on PARP-dependent DNA repairs of cancer cells to render cell susceptibility to PARP inhibitor therapy. Here we tested the hypothesis that XRCC2 loss sensitizes colorectal cancer (CRC) to PARP inhibitor in combination with radiotherapy (RT). We show that high levels of XRCC2 or PARP1 in LARC patients were significantly associated with poor overall survival (OS). Co-expression analyses found that low levels of PARP1 and XRCC2 were associated with better OS. Our in vitro experiments indicated that olaparib + IR led to reduced clonogenic survival, more DNA damage, and longer durations of cell cycle arrest and senescence in XRCC2-deficient cells relative to wild-type cells. Furthermore, our mouse xenograft experiments indicated that RT + olaparib had greater anti-tumor effects and led to long-term remission in mice with XRCC2-deficient tumors. These findings suggest that XRCC2-deficient CRC acquires high sensitivity to PARP inhibitor after IR treatment and supports the clinical development for the use of olaparib as a radiosensitizer for treatment of XRCC2-deficient CRC.

INTRODUCTION

Colorectal cancer (CRC) is among the most common cancers and a leading cause of cancer deaths worldwide [1]. The National Comprehensive Cancer Network guidelines currently recommend neoadjuvant chemoradiotherapy (neoCRT) as standard treatment for locally advanced rectal cancer (LARC) because it can significantly increase local control and improve cancer-specific survival [2, 3]. Most LARC patients who receive neoRT/neoCRT experience some tumor response, but other patients are resistant to this therapy. Many recent investigations reported that the response of an individual CRC patient is related to specific gene expression patterns in cancer cells [4]. The X-ray repair complementing defective repair (XRCC2) gene expression in cancer tissues had good pathologic responses and prognoses following neoRT; however, the other 28% of patients who tested negative for XRCC2 developed radioresistance and had poor prognoses [5]. It seems possible that when cancer cells lose XRCC2 function, they develop an alternative or compensatory pathway(s) for DNA repair. Therefore, agents that specifically target and radiosensitize tumor cells may be an effective treatment for patients with radioresistant tumors. For example, tumor cells that have BRCA inactivation remain sensitive to inhibition of poly (ADP-ribose) polymerase (PARP) due to their deficiency in homologous recombination repair (HRR) [6, 7].

RT kills cancer cells mostly by inducing DNA damage, and double-strand breaks (DSB) are the most toxic type of DNA damage [8]. Cells repair DSBs by non-homologous end joining (NHEJ) or HRR [9]. The PARP family of proteins plays a key role in a variety of cellular processes that includes DNA repair, chromatin modulation, and aspects of the replication stress response [10, 11]. PARP1 is the first and best-characterized member of the PARP family. PARP1 functions in the detection and initiation of DNA repair, and plays a role in repairing most types of DNA damage, including single-strand breaks (SSBs) and DSBs [12]. Because of the essential role of PARP in the recognition and repair of DSBs, several researchers examined the effect of PARP inhibitors on the sensitization of tumors defective in HRR following induction of DSBs with ionizing radiation (IR). They reported the accumulation of DNA DSBs and increased cell death [13–15].

HRR activity in tumor cells is a key factor for predicting whether treatment with a PARP1 inhibitor will be successful [16]. The XRCC2 protein functions in HRR, in that it participates in the repair of DSBs [17, 18]. Previous research showed that inhibition of XRCC2 sensitized CRC cells to radiation due to the inhibition of HRR [5]. This led us to hypothesize that PARP1 inhibitors have the potential for use as radiosensitizers in patients with XRCC2-deficient CRC because they increase the therapeutic benefit provided by RT.
Therefore, we examined LARC patients, in vitro models of CRC, and an in vivo model of CRC in which the tumors had different XRCC2 status to assess the radiosensitizing effect of olaparib, a drug approved for the treatment of several cancers with BRCA mutations.

**MATERIALS AND METHODS**

**Patients**  
A total of 167 LARC patients were examined at Sun Yat-sen University and Henan University. All patients had newly diagnosed LARC and received neoCRT from January 2010 to December 2016. The inclusion criteria were the presence of one primary lesion, completion of a standard neoCRT regimen, receipt of radical surgical resection, and completion of adjuvant chemotherapy with a capecitabine, XELOX, or mFOLFOX6 regimen. All biopsy samples were collected before neoCRT, as previously described [5]. The use of tissue blocks was approved by the Institutional Ethics Review Board of Sun Yat-sen University and Henan University. All patients provided written informed consent for participation.

**CRC cell lines**  
Two human CRC cell lines (HCT116 and SW480) were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and were grown according to the guidelines of the ATCC. Both cell lines were verified by short tandem repeat analysis (China Center for Type Culture Collection, Wuhan, China). The cells were cultured in DMEM (DMEM, Biological Industries, USA) supplemented with 10% Fetal Bovine Serum (FBS, Hyclone, USA) and 1% penicillin/streptomycin. All cells were cultured in a humidified air incubator containing 5% CO₂ at 37 °C. Cells with stable knockdown of XRCC2 (Sh- XRCC2) or with nonsilencing vector (control) were generated as previously described [5, 19]. Quantitative RT-PCR and western blotting were used to determine the extent of knockdown.

**Western blotting**  
For western blotting, proteins were first separated using 8–10% SDS-PAGE and the proteins were then electrotransferred to PVDF membranes (Millipore, Billerica, MA, USA). The sections were then deparaffinized and rehydrated, antigen retrieval performed, slides were incubated overnight with 70% ethanol at 20 °C, and then staining was performed as described in the in vitro experiments (above). Five images of randomly selected fields were recorded using an inverted microscope. Then blue-stained (senescent) cells and unstained (non-senescent) cells were counted using a computer. The percentages of positive cells were plotted using GraphPad Prism version 8.0.

**Immunohistochemistry**  
IHC assays were performed as previously described in detail [20]. First, formalin-fixed and paraffin-embedded tissue sections (4-μm thick) were prepared. The sections were then deparaffinized and rehydrated, antigen retrieval performed, and blocking was applied. All slides were incubated overnight at 4 °C with anti- XRCC2 (1:200, Ab180752; Abcam), anti-PARP1 (1:200; #ab32138; Abcam), or anti-h2AX (1:100; D17A3; Cell Signaling Technology), and then with a secondary antibody (Vectorstain ABC kit). Finally, 3, 3-diaminobenzidine (DAB) was used for staining and hematoxylin for counter-staining.

**Animals and in vivo studies**  
The Henan University Animal Care and Use Committee approved all in vivo experiments. Mice were sacrificed by an inhalant overdose of carbon dioxide (CO₂, 10–30%), followed by cervical dislocation. All efforts were made to minimize suffering. Experiments using tumor xenografts were performed as previously described in detail [21]. First, 6 × 10^6 SW480 cells were suspended in 100 μL of PBS. Cells were then subcutaneously implanted into the right flanks of female BALB/c nude mice that were 4–5 weeks old and weighed 15–18 g (SLRC Laboratory Animal Co). When the tumor volume was about 100 mm³, mice were separated into a DMSO group, olaparib group, RT + DMSO group, or RT + olaparib group. Mice received these treatments by oral gavage once per day for 12 consecutive days. Mice in the RT + DMSO and RT + olaparib groups received fractionated radiotherapy (2 Gy every other day for 5 days) at 1 h after oral gavage; a lead plate was used to provide coverage and assure that IR was only applied to the xenograft region. Tumors were measured using a digital caliper and volume was calculated as 0.52 × width² × length. Mice were euthanized and tumors were harvested 2 days after the last dose of olaparib or oralipib-RT. For long-term studies, mice were treated with 5-FU, an oral drug, for 28 days and then sacrificed. All efforts were made to minimize suffering.

**Statistical analysis**  
All results were confirmed in at least three independent experiments; one-way and two-way analysis of variance tests were used for comparisons of the results of the in vivo and in vitro experiments, and correction for multiple comparisons was performed using the Tukey or Sidak test, as appropriate. Each value was expressed as mean ± standard deviation (SD). A P value <0.05 was considered significant. All statistical analyses were performed using GraphPad Prism version 8.0.

**RESULTS**  
High expression of XRCC2 and PARP1 is associated with poor prognosis in LARC patients who received neoRT. Previous research showed that XRCC2 expression in pretreatment biopsy specimens was associated with response to neoRT in LARC patients [5], and that greater expression of XRCC2 was associated with reduced sensitivity to PARP1 inhibition [22]. We therefore investigated the relationship of XRCC2/PARP1 coexpression with the efficacy of RT in patients with LARC.
The expression of XRCC2 and PARP1 in biopsy tumor specimens collected from 167 LARC patients before treatment with neoCRT followed by surgery indicated that 57 samples (34.1%) were XRCC2− and 52 samples (31.1%) were PARP1+ (Fig. 1A). Kaplan–Meier survival analysis (Fig. 1B, C) indicated poor overall survival (OS) in patients with high levels of XRCC2 (P = 0.006) or PARP1 (P = 0.0001). XRCC2/PARP1 coexpression analysis in the whole cohort indicated that patients who had tumors with low coexpression had better OS (P = 0.002; Fig. 1D). These data suggest that simultaneous targeting of XRCC2 and PARP1 could be a promising treatment for selected LARC patients. We therefore further examined the potential of this treatment regimen using in vitro and animal studies.

Olaparib increased the radiosensitivity of XRCC2-deficient CRC cells

Previous studies established a line of CRC cells with successful knockdown of XRCC2 [5, 19]. We first confirmed the knockdown of XRCC2 in these cells using western blotting (Fig. 2A) and qRT-PCR (Fig. 2B). We then examined the survival of these cells following combined treatment with olaparib (a PARP inhibitor) and IR using the clonogenic survival assay (Fig. 2C, D). The results indicated the olaparib+IR regimen significantly reduced survival relative to IR alone (all P < 0.05), indicating that olaparib radiosensitized these CRC cells. Importantly, XRCC2-deficient cells had greater sensitivity to IR and greater olaparib-mediated radiosensitization than cells with empty vectors.

Olaparib + IR increased DNA damage in XRCC2-deficient CRC cells

IR causes DSBs and induces the rapid production of γH2AX, a marker of impaired cellular capacity to repair DSBs [23, 24]. We thus investigated the effects of olaparib on IR-induced DNA damage by using immunofluorescence to measure γH2AX in XRCC2-deficient CRC cells. After 48 h, treatment with olaparib alone led to no significant DNA damage, but treatment with olaparib+IR led to increased levels of γH2AX (Fig. 3A, B). Importantly, irradiated XRCC2-deficient cells had more γH2AX foci than XRCC2-expressing cells at 48 h when treated with olaparib. These data suggest that treatment with olaparib+IR led to more DNA damage in XRCC2-deficient CRC cells than in control cells with empty vectors.

Olaparib promoted G2/M phase arrest in XRCC2-deficient CRC cells after RT

Sustained arrest at the G2/M growth phase is a well-established cellular response to DNA damage [25]. Thus, we examined the effect of olaparib+IR on the fraction of XRCC2-deficient CRC cells that were arrested in the G2/M phase. In particular, we performed FACS analysis to compare CRC cells that had empty vectors with CRC cells that had XRCC2 depletion that were treated with olaparib, IR, or both (Fig. 4). The results showed that treatment with olaparib had no effect on the number of XRCC2-deficient cells in phase G2/M. However, IR + olaparib led to a significant arrest of the cell cycle at the G2/M phase in both cell lines (P < 0.01; Fig. 3A, B). Furthermore, olaparib+IR increased the percentage of cells in phase G2/M in XRCC2-deficient CRC cells compared to CRC cells with empty vectors (P < 0.01; Fig. 4A, B).

Olaparib accelerated senescence when combined with IR in XRCC2-deficient cells

Irreversible cell cycle arrest is a key feature of accelerated senescence. Thus, we analyzed the effect of different treatments on cell senescence using the β-gal assay (Fig. 5A). IR + olaparib significantly increased the proportion of β-gal-positivity in XRCC2-deficient cells relative to cells with empty vectors (P < 0.001; Fig. 5B). Agents that damage DNA primarily promote senescence via the p53/p21 signaling pathway [26], so we also analyzed the effects of different treatments on the levels of phospho-p53 and p21. The results indicated that XRCC2-deficient cells and cells with empty vectors had increased levels of phospho-p53 and p21 at 48 h after 10 Gy of IR, and olaparib treatment increased this effect. Moreover, the olaparib+IR treatment led to higher levels of phospho-p53 and p21 in XRCC2-deficient cells than in cells with empty vectors (Fig. 5C). These results indicated that olaparib enhanced the effect of IR in the induction of cell senescence.

Olaparib increased the radiosensitivity of XRCC2-deficient cells in a mouse xenograft model

We evaluated the effect of IR on olaparib sensitivity using mice xenograft experiments in which the two SW480 cell lines only differed in XRCC2 status (Fig. 6A). Strikingly, olaparib+RT prevented the growth of XRCC2-deficient tumors and was more effective than either treatment alone (Fig. 6B). We also determined...
whether olaparib+RT led to long-lasting effects by following mice that received this therapy for 30 days (2 weeks after the final treatment). The results indicated that XRCC2+/+ tumors regrew quickly following treatment cessation, but shXRCC2 tumors continued to shrink (Fig. 6C).

We then assessed the broader implications of these findings by harvesting tumors from all mice 2 days after the last treatment (Fig. 6A). The results indicated that γH2AX expression of tumor tissues following olaparib+RT treatment was significantly greater in XRCC2-deficient CRC cells (Fig. 6D). Although there was negligible staining following treatment with olaparib alone, there was notably increased activity of β-gal following treatment with olaparib+RT, especially in XRCC2-deficient CRC cells (Fig. 6E). The results of these xenograft tumor model experiments confirmed that olaparib increased the radiosensitivity of XRCC2-deficient CRC cells.
Fig. 4  Effect of olaparib on sensitization of XRCC2-deficient cancer cells to IR-induced phase G2/M arrest. A Cell cycle profiles of cells with (sh-XRCC2) and without (vector) XRCC2 knockdown at 48 h after the indicated treatment. B Quantification of flow cytometry results in the different treatment groups. Results show the means ± SDs from three independent experiments. **P < 0.01, ***P < 0.001.

Fig. 5  Effect of olaparib on senescence after in vitro IR treatment. A Representative images of senescence (β-gal activity) after 48 h in the different treatment groups (×40). B Quantification of microscopy results. Results show means ± SDs from three independent experiments. **P < 0.01, ***P < 0.001. C Representative western blotting of phospho-P53 and P21 in SW480 cells (left) and HCT116 cells (right) in the different treatment groups.
DISCUSSION
PARP1 inhibitors are therapeutic agents that increase cell death in tumors with deficiencies in HRR-mediated DNA repair, such as those with BRCA1 mutations [10, 27]. Thus, CRC cells that respond to PARP1 inhibitors are likely to have defects in DSB repair enzymes, even though BRCA mutations are rare in patients with CRC [28]. Previous studies showed that XRCC2-deficient CRC cells were sensitive to 5-fluorouracil (5FU) and RT [5, 19]. In particular, a study of 67 LARC patients treated with neoRT between 2010 and 2012 indicated that XRCC2 overexpression was associated with RT resistance and poor OS [5]. We examined these 67 patients and an additional 100 patients with LARC who were treated from 2013 to 2016 and described the results of all 167 patients herein. Our analysis of these 167 patients confirmed the previous observations. We also found that PARP1 overexpression was negatively associated with OS, and co-expression analyses indicated that low co-expression of PARP1 and XRCC2 was associated with a better OS. These results thus provide evidence that a PARP1 inhibitor (olaparib) may enhance the effect of RT on XRCC2-deficient CRCs.

Death of human tumor cells following RT is caused mainly due to the induction of DSBs, damage that can be repaired by HRR or NHEJ [29]. A recent study showed that XRCC2 deficiency sensitized CRCs to RT [5]. However, not all XRCC2-deficient cancer cells were sensitive to IR in vitro [5, 29]. IR induces complex DNA lesions that require repair via the HRR pathway (which depends on XRCC2), although the NHEJ pathway (which does not require XRCC2) can repair most of these lesions [29, 30]. This might explain the differences in radiosensitivity in our HRR deficient model.

Radiosensitization by treatment with a PARP1 inhibitor is apparently due to the inhibition of base excision repair. This leads to a delay in the repair of SSBs, and the collision of these SSBs with replication forks transforms them into 1-ended DSBs. These DSBs can only be repaired by HRR [31]. Thus, the application of a PARP1 inhibitor with RT leads to greater inhibition in BRCA2− than BRCA2+ breast cancers [32]. Other studies reported that
radiosensitization by PARP1 inhibitors was greater when a variety of DNA DSB repair deficiencies were present, such as deficiencies in Ligase IV and RAD51C [33, 34]. Our results are consistent with these previous studies, in that olaparib treatment led to radiosensitization of CRC cells, particularly in tumors with XRCC2 deficiencies. Our in vitro studies of the effect of IR + olaparib indicated radiosensitization in XRCC2-deficient cell lines, manifested as decreased colony formation, increased γ-H2AX persistence, increased cellular senescence, and cell cycle arrest. We also confirmed the effectiveness of this combination treatment in vivo using XRCC2-deficient tumor xenographs, which had delayed growth relative to xenographs with empty vectors.

We also compared the extent of DNA breaks from IR alone vs. IR + olaparib by measuring the levels of γ-H2AX. As expected, the different responses to these treatments were associated with different residual levels of total DNA damage. This may be because there is a need for repeated cycles of DNA synthesis so that unrepaired single-strand DNA breaks caused by IR are converted to DSBs, which cannot be repaired because of XRCC2 deficiency. Cell cycle regulation is an important biological process that also affected radiosensitivity, and cells are typically most sensitive during the G2/M phase [35]. There is evidence that PARP may promote G2/M arrest following genotoxic stress [36]. Our data on different CRC cell lines showed that IR enhance growth arrest and senescence [33]. This lack of a role manifested predominantly as an extension of growth arrest PARP1 inhibitor combined with RT showed that radiosensitization manifested as apoptosis [38]. Our present results showed that IR and senescence and that there was little or no contribution from PARP inhibitors did not increase radiation-induced apoptosis [39, 40]. These results are in accordance with the study of Alotaibi et al., who demonstrated that PARP inhibitors did not increase radiation-induced apoptosis in DNA repair-deficient tumor cells, but did markedly enhance growth arrest and senescence [33]. This lack of a role for apoptosis is not surprising, because RT is believed to mainly kill cells by induction of "mitotic catastrophe" (aberrant mitosis), in which large non-viable cells that have micronuclei or multiple nuclei are formed [39, 40].

Phospho-p53 activates many cellular responses, including initiation of senescence and cell cycle arrest after IR [41, 42]. The results presented here showed that olaparib + IR increased the level of phospho-p53 in XRCC2-deficient CRC cells. We also observed increased p21 levels in XRCC2-deficient CRC cells after IR, which is noteworthy because p21 inhibits cyclin-dependent-kinases, phospho-p53 induction of p21 leads to arrest at the G2/M phase. We showed that IR treatment led to a significant arrest of the cell cycle in phase G2 and that this arrest persisted for 72 h. In addition to its role in cell cycle arrest, p21 activation is also an initial step of accelerated senescence [43].

DATA AVAILABILITY
The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES
1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.
2. van Gijn W, Marijnissen CA, Nagtegaal ID, Kranenburg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–82.
3. Ma B, Gao P, Wang H, Xu Q, Song Y, Huang X, et al. What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients. Int J Cancer. 2017;141:1052–65.
4. Wang XC, Yue X, Zhang RX, Liu TY, Pan ZZ, Yang MJ, et al. Genome-wide RNAi screening identifies RFC4 as a factor that mediates radiosensitivity in colorectal cancer by facilitating nonhomologous end joining repair. Clin Cancer Res. 2019;25:4567–79.
5. Qin CJ, Song XM, Chen ZH, Ren XQ, Xue KW, Jing H, et al. XRCC2 as a predictive biomarker for radiosensitivity in locally advanced rectal cancer patients under-going preoperative radiotherapy. Oncotarget. 2015;6:32193–204.
6. Dedes KJ, Wilkerson PM, Wetterskog D, Weigel B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011;10:1192–9.
7. Fong PC, Ross DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34.
8. Pastewa E, Blasja J. Non-homologous DNA end joining. Acta Biochim Pol. 2003;50:891–908.
9. Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair. 2007;6:923–35.
10. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152–8.
11. D’Andre A, Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair. 2018;71:172–6.
12. Patel AG, Sarkania JN, Kaufmann SH. Nonhomologous end joining drives poly (ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA. 2011;108:3406–11.
13. Nonnekens J, van Kranenburg M, Beerens CE, Moukas M, Doukas M, van Eijck CH, et al. Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib. Theranostics. 2016;6:1821–32.
14. Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carl AL, O’Connor MJ, et al. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiotther Oncol. 2015;116:358–65.
15. Michmerhuizen AR, Pesch AM, Moubadder L, Chandler BC, Wilder-Romans K, Cameron M, et al. PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation. Mol Cancer Ther. 2019;18:2063–73.
16. Mukhopadhyay A, Elattar A, Cerbkinskaite A, Wilkinson SJ, Drew Y, Kyle S, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res. 2010;16:2344–51.
17. Tambini CE, Spinke KG, Ross CJ, Hill MA, Thacker J. The importance of XRCC2 in RAD51-related DNA damage repair. DNA Repair. 2010;9:517–25.
18. Johnson RD, Liu N, Jasin M. Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination. Nature. 1999;401:397–9.
19. Zhang YZ, An JH, Liu YX, Wu XC, Han SS, Ren XQ, et al. XRCC2-deficient cells are highly sensitive to 5-fluorouracil in colorectal cancer. Cell Physiol Biochem. 2017;43:1207–19.
20. Azad A, Jackson S, Cullinan C, Natoli A, Neilson PM, Callen DF, et al. Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells. Mol Cancer Res. 2011;9:1696–707.
21. Park Y, Chui MH, Suryo Rahmanto Y, Yu ZC, Shamanna RA, Bellani MA, et al. Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy. Clin Cancer Res. 2019;25:5584–94.
22. Xu K, Song X, Chen Z, Qin C, He Y. XRCC2 rs3218536 polymorphism decreases the sensitivity of colorectal cancer cells to poly(ADP-ribose) polymerase 1 inhibitor. Oncol Lett. 2014;8:1222–8.
23. Redon CE, Nakamura AJ, Gouliaeva K, Rahman A, Blakely WF, Bonner WM. The use of gamma-H2AX as a biodosimeter for total-body radiation exposure in non-human primates. PLoS ONE. 2010;5:e15544.
24. Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, et al. Histone gammaH2AX as a potential radiation biomarker in human cancer cells. Proc Natl Acad Sci USA. 2004;101:3781–5.
25. Krempler A, Deckbar D, Jeggo PA, Lobrich M. An imperfect G2M checkpoint brings to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients. Int J Cancer. 2017;141:1052–65.
42. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282:1497–501.

43. Ewald JA, Desotelle JA, Widing G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst. 2010;102:1536–46.

**AUTHOR CONTRIBUTIONS**
CQ and XS designed the experiments. EZ and KX provided advice on the experimental design and data presentation. CQ, QL, and ZJ performed in vivo and in vitro experiments. HJ and WL performed the immunostaining and analyses. All authors contributed to manuscript writing and editing.

**FUNDING INFORMATION**
This study was supported by grants from the National Natural Science Foundation of China (NSFC-U1504818), a Scientific and technological project in Henan Province (222102310134), and the Medical Science and Technique Foundation of Henan Province (SBGJ202002097).

**COMPETING INTERESTS**
The authors declare no competing interests.

**ADDITIONAL INFORMATION**
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-022-04967-7.

Correspondence and requests for materials should be addressed to Changjiang Qin or Xinming Song.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022